During the period 25 June 2018 – 29 June 2018, shares in Karo Pharma have been repurchased as follows.
volume (number of shares)
|Weighted average share
price per day (SEK)
|Total daily transaction
|25 June 2018||104 906||29.278900||3 125 045|
|26 June 2018||100 000||29.206900||2 920 690|
|27 June 2018||78 000||29.595300||2 308 433|
|28 June 2018||98 332||29.657800||2 916 311|
|29 June 2018||79 578||28.621200||2 357 196|
All acquisitions have been carried out on Nasdaq Stockholm by Swedbank in cooperation with Kepler Cheuvreux SA on behalf of Karo Pharma. Following the above acquisitions, Karo Pharma’s holding of own shares amounts to 844,105 shares as of 29 June 2018. The total number of shares in Karo Pharma is 164,332,782.
A full breakdown of the transactions pursuant to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is available at www.karopharma. (http://www.karopharma.se)com. The total volume of Karo Pharma’s shares which have been bought back within the repurchase programme from 18 June 2018 until and including 29 June 2018 amounts to 844,105 shares. In total a maximum of 2 464 990 shares may be repurchased. For information about all transactions in the buy-back programme see the following link to Nasdaq Stockholm’s website: http://www.nasdaqomx.com/transactions/markets/nordic/corporate-actions/stockholm/repurchases-of-own-shares.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Peter Blom, CEO, +46 (0) 70-655 56 98 or email@example.com
ABOUT KARO PHARMA
Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
The information was submitted for publication, through the above contact person´s agency, at 08.00 CEST on 2 July 2018. This press release is also available at www.karopharma.se and www.newsroom.cision.com.